Natco, Akorn form agreement for injectable drugs

By Elaine Rigoli

Tampa, Fla., April 24 - Natco Pharma Ltd. and Akorn, Inc. announced a collaboration to commercialize two abbreviated New Drug Application injectable drug products.

The two aNDA drug products will focus on the anti-emetic and cancer related markets and have a combined current market size of about $875 million, according to a news release.

Under the agreement, Natco will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic and home health care markets in the United States and Canada, the release said.

Akorn, located in Buffalo Grove, Ill., manufactures and markets sterile specialty pharmaceuticals.

Natco is a pharmaceutical company located in Hyderabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.